Inhibitors of Acetyltransferase Domain of N-Acetylglucosamine-1-Phosphate-Uridyltransferase/ Glucosamine-1-Phosphate-Acetyltransferase (Glmu). Part 1: Hit to Lead Evaluation of a Novel Arylsulfonamide Series.
Green, O.M., McKenzie, A.R., Shapiro, A.B., Otterbein, L., Ni, H., Patten, A., Stokes, S., Albert, R., Kawatkar, S., Breed, J.(2012) Bioorg Med Chem Lett 22: 1510
- PubMed: 22297115 
- DOI: https://doi.org/10.1016/j.bmcl.2012.01.016
- Primary Citation of Related Structures:  
4AA7, 4AAW, 4AC3 - PubMed Abstract: 
A novel arylsulfonamide-containing series of compounds represented by 1, discovered by highthroughput screening, inhibit the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). X-ray structure determination confirmed that inhibitor binds at the site occupied by acetyl-CoA, indicating that series is competitive with this substrate. This letter documents our early hit-to-lead evaluation of the chemical series and some of the findings that led to improvement in in-vitro potency against Gram-negative and Gram-positive bacterial isozymes, exemplified by compound 40.
Organizational Affiliation: 
Infection Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, MA 02451, USA. oluyinka.green@astrazeneca.com